The Johns Hopkins University;Nacuity Pharmaceuticals, Inc.
发明人:
Campochiaro, Peter A.,Hartman, Daniel
申请号：
AU2019261762
公开号：
AU2019261762A1
申请日:
2019.11.07
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
#$%^&*AU2019261762A120191128.pdf#####ABSTRACT The present invention includes a method for the treatment of retinitis pigmentosa in a human that comprises administering to the human a therapeutically effective amount of Nacetylcysteine amide (NACA). In accordance with an embodiment, the present invention provides a method for the treatment of retinitis pigmentosa in an animal that comprises administering to the animal a therapeutically effective amount of N-acetylcystein amide (NACA).WO 2016/073931 PCT/US2015/059589 1/6 400 SCOTOPIC B-WAVE AMPLITUDE Rdl7mg/m NACA 350 - -- Rd0 7mg/ml NAC 300=250 200 150 S10050 0 FIG. 1A -3.5 -2.5 -1.5 -0.5 0 0.5 1.5 LOG FLASH INTENSITY -0- Rd0 CONTROL 250 PHOTOPIC B-WAVE AMPLITUDE -A- Rd0 7mg/ml NACA -x- Rd0 7mg/ml NAC 200 150 100 50 0 FIG. lB 0.6 1.0 1.4 LOG FLASH INTENSITY (log(P)cd.s/m2 SCOTOPIC B-WAVE AMPLITUDE -0- Rd0 CONTROL 40-A-Rd0 7mg/ml NACA 350 - -x-RdlO 7mg/ml NAC 300 250 200 I=i 150 C<； 100 50 0 IFIG. IC -3.5 -2.5 -1.5 -0.5 0 0.5 1.5 LOG FLASH INTENSITY STRSTITTTF SHEET (RILF 261
